Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02118467 · ClinicalTrials.gov registry record · Phase 4
Vasoactive Drugs in Intensive Care Unit
A Phase 4 study of Shock, sponsored by University of Chicago.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 836
- Enrollment target
- 1
- Study location
NCT02118467: Recruiting Phase 4 study of Shock, sponsored by University of Chicago.
NCT02118467 is a Phase 4 study of Shock that is actively recruiting participants, run by University of Chicago. The registered enrollment target is 836 participants, above the 389-participant average among 9 other Shock trials with a reported enrollment target (115% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02118467, a Phase 4 study of Shock, is actively recruiting participants, sponsored by University of Chicago.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 836 participants
- Enrollment target
- 1
- Study location
Study Summary
The investigators hypothesis is that for ICU patients with shock, the use of the vasoactive drugs phenylephrine and vasopressin will reduce tachydysrhythmias when compared to norepinephrine and epinephrine. To investigate this hypothesis, the investigators are conducting a randomized double blind controlled trial comparing phenylephrine and vasopressin vs. norepinephrine and epinephrine in ICU patients with shock that is not responsive to IV fluids. All patients admitted to the adult intensive care units at the University of Chicago will be screened for eligibility.
Conditions Studied
Interventions
- DRUG Norepinephrine
- DRUG Epinephrine
- DRUG Vasopressin
- DRUG Phenylephrine
Study Locations (1)
Illinois
- University of Chicago Medical Center - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 836 participants |
| Start Date | 2014-05-15 |
| Est. Completion | 2026-12-01 |
| Phase | Phase 4 |
What NCT02118467 shows while recruiting
NCT02118467 is an interventional study that assigns participants to a tested intervention. The registered 836 participants enrollment target is mid-sized for trials with a published cap, above the 389-participant average among 9 other Shock trials with a reported enrollment target (115% higher).
The record links to 1 condition, with Shock appearing as the primary indexed condition, and to 4 interventions - of which Norepinephrine is the first listed.
NCT02118467 reports a single indexed study location in Illinois.
Frequently Asked Questions
What is clinical trial NCT02118467 about?
NCT02118467 is a clinical study titled "Vasoactive Drugs in Intensive Care Unit". The investigators hypothesis is that for ICU patients with shock, the use of the vasoactive drugs phenylephrine and vasopressin will reduce tachydysrhythmias when compared to norepinephrine and epinephrine. To investigate this hypothesis, the investigators are conducting a randomized double blind co...
What is the current status of trial NCT02118467?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 836 participants. The study started on 2014-05-15. Estimated completion is 2026-12-01.
What conditions does trial NCT02118467 study?
This clinical trial studies the following conditions: Shock.
What interventions are being tested in trial NCT02118467?
The interventions under investigation include: Norepinephrine (DRUG), Epinephrine (DRUG), Vasopressin (DRUG), Phenylephrine (DRUG).
Who is sponsoring clinical trial NCT02118467?
This trial is sponsored by University of Chicago, which has 796 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02118467 being conducted?
This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Shock
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02118467's enrollment target sits among peer trials
836 3rd of 9 higher than 7 of 9 other Shock trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Shock trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Central Line Study
RECRUITING · Phase 4
-
Hemodynamic Response to Angiotensin-II When Used as the Second Vasopressor Agent for Septic Shock
RECRUITING · Phase 4
-
Effect of Nebulized Bronchodilators on Heart Rate
COMPLETED · Phase 4
-
Assessment of Stroke Volume in Shock Using Echocardiography Versus Bioreactive Impedance
RECRUITING
-
Resuscitative TEE Collaborative Registry
RECRUITING
-
Evaluating Fluid Responsiveness in ICU Patients Using VTI and Trendelenburg Positioning
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02422550 · 837 participants
Imaging Acquisition and Analysis Methods for Optimization of MRI Radiation Oncology Simulation and Response Assessment
- NCT03670524 · 835 participants · NA
Health, Environment and Action in Louisville (HEAL) Green Heart Louisville Project
- NCT04831580 · 840 participants · NA
A Trial of Robotic Versus Open Hysterectomy Surgery in Cervix Cancer
- NCT04976881 · 840 participants · NA
Promoting Preconception Care and Diabetes Self-Management Among Reproductive-Aged Women With Diabetes
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI